High-sensitivity C-reactive protein: To measure or not to measure?

Open Clinical Chemistry Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 10-18

  Nakou, E S ^a   Elisaf, M S ^a   Liberopoulos, E N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherogenesis; Atherosclerosis; C reactive protein; Cardiovascular disease; Inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MEDICAL DECISION MAKING; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RESTENOSIS; SECONDARY PREVENTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78249258736     PISSN: None     EISSN: 18742416     Source Type: Journal    
DOI: 10.2174/1874241601003020010     Document Type: Article

References (109)

1. Ridker, P.M.; Glynn, R.J.; Hennekens, C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation, 1998, 97, 2007-2011.
2. Ridker, P.M.; Buring, J.E.; Shih, J.; Matias, M.; Hennekens, C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation, 1998, 98, 731-733.
3. Ridker, P.M.; Rifai, N.; Rose, L.; Buring, J.E.; Cook, N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med., 2002, 347, 1557-65.
4. Wilson, M.W.; Marno, C.R.; Andrew, J.B. The novel role of Creactive protein in cardiovascular disease:risk marker or pathyogen. Int. J. Cardiol., 2006, 106, 291-297.
5. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420, 868-74.
6. Yasojima, K.; Schwab, C.; McGeer, E.G.; McGeer, P.L.; Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol., 2001, 158, 1039-1051.
7. Pepys, M.B.; Baltz, M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol., 1983, 34, 141-212.
8. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med., 1999, 340, 448-454.
9. Blake, G.J.; Ridker, P.M. C-reactive protein: a surrogate risk marker or mediator of atherothrombosis? Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003, 285, R1250-1252.
10. Whitehead, A.S.; Bruns, G.A.; Markham, A.F.; Colten, H.R.; Woods, D.E. Isolation of human C-reactive protein complementary DNA and localization of the gene to chromosome 1. Science, 1983, 221, 69-71.
11. Kathiresan, S.; Larson, M.G.; Vasan, R.S.; Guo, C.Y.; Gona, P. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation, 2006, 113, 1415-23.
12. Kivimäki, M.; Lawlor, D.A.; Smith, G.D.; Eklund, C.; Hurme, M. Variants in the CRP gene as a measure of lifelong differences in average C-reactive protein levels: the Cardiovascular Risk in Young Finns Study, 1980-2001. Am. J. Epidemiol., 2007, 166, 760-4.
13. Crawford, D.C.; Sanders, C.L.; Qin, X.; Smith, J.D., Shephard, C. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation, 2006, 114, 2458-65.
14. Lange, L.A.; Carlson, C.S.; Hindorff, L.A.; Lange, E.M.; Walston, J. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA, 2006, 296, 2703-11.
15. Wang, Q.; Hunt, S.C.; Xu, Q.; Chen, Y.E.; Province, M. Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H2752-7.
16. Zhang, L.; Kao, W.H.; Berthier-Schaad, Y.; Plantinga, L.; Fink, N. C-Reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am. J. Kidney Dis., 2007, 49, 118-26.
17. Elliott, P.; Chambers, J.; Zhang, W.; Clarke, R.; Hopewell, J.C.; Peden, J.F.; Erdmann, J.; Braund, P.; Engert, J.C.; Bennett, D.; Coin, L.; Ashby, D.; Tzoulaki, I.; Brown, I.J.; Mt-Isa, S.; McCarthy, M.I.; Peltonen, L.; Freimer, N.B.; Farrall, M.; Ruokonen, A.; Hamsten, A.; Lim, N.; Froguel, P.; Waterworth, D.M.; Vollenweider, P.; Waeber, G.; Jarvelin, M.R.; Mooser, V.; Scott, J.; Hall, A.S.; Schunkert, H.; Anand, S.S.; Collins, R.; Samani, N.; Watkins, H.; Kooner, J.S. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA, 2009, 302, 37-48.
18. Zacho, J.; Tybjaerg-Hansen, A.; Jensen, J.S.; Grande, P.; Sillesen, H.; Nordestgaard, B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med., 2008, 359, 1897-908.
19. Grammer, T.B.; März, W.; Renner, W.; Böhm, B.O.; Hoffmann, M.M. C-reactive protein genotypes associated with circulating Creactive protein but not with angiographic coronary artery disease: the LURIC study. Eur. Heart, 2009, 30, 170-82.
20. Rifai, N.; Ridker, P.M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem., 2001, 47, 403-11.
21. Burnett, J.R.; Watts, G.F.; Vasikaran, S.D. C-reactive protein: a new cardiovascular risk factor? Med. J. Aust., 2000, 173, 117-8.
22. de Ferranti, S.D.; Rifai, N. C-reactive protein: a non-traditional serum marker of cardiovascular risk. Cardiovasc. Pathol., 2007, 16, 14-21.
23. Ledue, T.B.; Rifai, N.; Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin. Chem., 2003, 49, 1258-71.
24. Rothkrantz-Kos, S.; Schmitz, M.P.; Bekers, O.; Menheere, P.P.; van Dieijen-Visser, M.P. High sensitivity C-reactive protein methods examined. Clin. Chem., 2002, 48, 359-62.
25. Pearson, T.A.; Mensah, G.A.; Alexander, R.W.; Anderson, J.L.; Cannon, III R.O.; Criqui, M.; Fadl, Y.Y.; Fortmann, S.P.; Hong, Y.; Myers, G.L.; Rifai, N.;Smith, Jr S.C; Taubert, K.; Tracy, R.P.; Vinicor, F. Centers for disease control and prevention; american heart association markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for health-care professionals from the centers for disease control and prevention and the american heart association. Circulation, 2003, 107, 499-511.
26. Yasojima, K.; Schwab, C.; McGeer, E.G.; McGeer, PL. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res, 2000, 887, 80-89.
27. Black, S.; Kushner, I.; Samols, D. C-reactive protein. J. Biol. Chem., 2004, 279, 48487-48490.
28. Davey, S.G.; Timpson, N.; Lawlor, D. C-reactive protein and cardiovascular disease risk: Still an unknown quantity? Ann. Intern. Med., 2006, 145, 70-72.
29. Kuller, L.H.; Tracy, R.P.; Shaten, J.; Meilahn, E.N. Relation of Creactive protein and coronary heart-disease in the MRFIT nested case control study. Am. J. Epidemiol., 1996, 144, 537-547.
30. Ridker, P.M.; Cushman, M.; Stampfer, M.J.; Tracy, R.P.; Hennekens, C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med., 1997, 336, 973-979.
31. Koenig, W.; Sund, M.; Fröhlich, M.; Fischer, H.G.; Löwel, H.; Döring, A.; Hutchinson, W.L.; Pepys, M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation, 1999, 99, 237-242.
32. Danesh, J.; Whincup, P.; Walker, M.; Lennon, L.; Thomson, A.; Appleby, P.; Gallimore, J.R.; Pepys, M.B. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ, 2000, 321, 199-204.
33. Morrow, D.A.; Ridker, P.M. C-reactive, inflammation, and coronary risk. Med. Clin. North Am., 2000, 84, 149-161.
34. Ridker, P.M.J.; Hennekens, C.H.; Buring, J.E.; Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. Med., 2000, 342, 836-843.
35. Ridker, P.M.; Stampfer, M.J.; Rifai, N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocystein, lipoprotein (a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA, 2001, 285, 2481-2485.
36. Nakou, E.S.; Liberopoulos, E.N.; Milionis, H.J.; Elisaf, M.S. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr. Vasc. Pharmacol., 2008, 6, 258-70.
37. Danesh, J.; Whincup, P.; Walker, M.; Lennon, L.; Thomson, A.; Appleby, P.; Gallimore, J.R.; Pepys, M.B. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ, 2000, 321, 199-204.
38. Tohidi, M.; Hadaegh, F.; Harati, H.; Azizi, F. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Int. J. Cardiol., 2009, 132, 369-74.
39. Melander, O.; Newton-Cheh, C.; Almgren, P.; Hedblad, B.; Berglund, G.; Engström, G.; Persson, M.; Smith, J.G.; Magnusson, M.; Christensson, A.; Struck, J.; Morgenthaler, N.G.; Bergmann, A.; Pencina, M.J.; Wang, T.J. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA, 2009, 302, 49-57.
40. Ridker, P.M.; Rifai, N.; Clearfield, M.; Downs, J.R.; Weis, S.E.; Miles, J.S.; Gotto, A.M. Jr. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med., 2001, 344, 1959-65.
41. de Beer, F.C.; Hind, C.R.; Fox, K.M.; Allan, R.M.; Maseri, A.; Pepys, M.B. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br. Heart J., 1982, 47, 239-243.
42. Pietilä, K.O.; Harmoinen, A.P.; Jokiniitty, J.; Pasternack, A.I. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur. Heart J., 1996, 17, 1345-1349.
43. Ueda, S.; Ikeda, U.; Yamamoto, K.; Takahashi, M.; Nishinaga, M.; Nago, N.; Shimada, K. C-reactive protein as a predictor of cardiac rupture after acute myocardial infarction. Am. Heart J., 1996, 131, 857-860.
44. Anzai, T.; Yoshikawa, T.; Shiraki, H.; Asakura, Y.; Akaishi, M.; Mitamura, H.; Ogawa, S. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation, 1997, 96, 778-784.
45. Ridker, P.M.; Rifai, N.; Pfeffer, M.A.; Sacks, F.M.; Moye, L.A.; Goldman, S.; Flaker, G.C.; Braunwald, E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998, 98, 839-844.
46. Sabatine, M.S.; Morrow, D.A.; Jablonski, K.A.; Rice, M.M.; Warnica, J.W.; Domanski, M.J.; Hsia, J.; Gersh, B.J.; Rifai, N.; Ridker, P.M.; Pfeffer, M.A.; Braunwald, E. PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation, 2007, 115, 1528-1536.
47. Markuszewski, L.; Rysz, J.; Makowski, M.; Debska, A.; Pietruszynski, R. C-reactive protein as a predictor of major adverse cardiac events (MACE) after percutaneous coronary intervention? Arch. Med. Sci., 2005, 1(3), 152-156.
48. Gaspardone, A.; Crea, F.; Versaci, F.; Tomai, F.; Pellegrino, A.; Chiariello, L.; Gioffrè, P.A. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am. J. Cardiol., 1998, 82, 515-518.
49. Karaca, I.; Aydin, K.; Yavuzkir, M.; Ilkay, E.; Akbulut, M. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. J. Int. Med. Res., 2005, 33, 389-396.
50. Iarlykova, E.I.; Kuchkina, N.V.; Vorob'eva, E.I. C-reactive protein as possible early prognostic marker of restenosis development in coronary artery stents. Kardiologiia, 2002, 42, 11-13.
51. Yip, H.K.; Hung, W.C.; Yang, C.H.; Chen, Y.H.; Cheng, C.I. Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting. Circ. J., 2005, 69, 1202-1207.
52. Gach, O.; Legrand, V.; Biessaux, Y.; Chapelle, J.P.; Vanbelle, S.; Pierard, L.A. Long-term prognostic significance of high-sensitivity C-reactive protein before and after coronary angioplasty in patients with stable angina pectoris. Am. J. Cardiol., 2007, 99, 31-35.
53. van der Harst, P.; Voors, A.A.; Volbeda, M.; Buikema, H.; van Veldhuisen, D.J.; van Gilst, W.H. Usefulness of preoperative Creactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am. J. Cardiol., 2006, 97, 1697-1701.
54. Ridker, P.M.; Cannon, C.P.; Morrow, D.; Rifai, N.; Rose, L.M.; mCcABE, ch.; Pfeffer, M.A.; Braunwald, E. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med., 2005, 352, 20-28.
55. Ridker, P.M.; Morrow, D.A.; Rose, L.M.; Rifai, N.; Cannon, C.P.; Braunwald, E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J. Am. Coll. Cardiol., 2005, 45, 1644-1648.
56. Mega, J.L.; Morrow, D.A.; Cannon, C.P.; Murphy, S.; Cairns, R.; Ridker, P.M.; Braunwald, E. Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J. Thromb. Thrombolysis, 2006, 22, 71-76.
57. Wilson, P.W.; Nam, B.H.; Pencina, M.; D'Agostino, R.B.Sr.; Benjamin, E.J.; O'Donnell, C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern. Med., 2005, 165, 2473-8.
58. Danesh, J.; Wheeler, J.G.; Hirschfield, G.M.; Eda, S.; Eiriksdottir, G.; Rumley, A.; Lowe, G.D.; Pepys, M.B.; Gudnason, V. Creactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med., 2004, 350, 1387-97.
59. Schlager, O.; Exner, M.; Mlekusch, W.; Sabeti, S.; Amighi, J.; Dick, P.; Wagner, O.; Koppensteiner, R.; Minar, E.; Schillinger, M. C-reactive protein predicts future cardiovascular events in patients with carotid stenosis. Stroke, 2007, 38, 1263-1268.
60. Flegar-Mestric, Z.; Vrhovski-Hebrang, D.; Preden-Kerekovic, V.; Perkov, S.; Hebrang, A.; Grga, A.; Janus, D.; Vidjak, V. C-reactive protein level in severe stenosis of cerebral arteries. Cerebrovasc. Dis., 2007, 23, 430-434.
61. Mullenix, P.S.; Steele, S.R.; Martin, M.J.; Starnes, B.W.; Andersen, C.A. C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis. Arch. Surg., 2007, 142, 1066-1071.
62. Nambi, V.; Hoogeveen, R.C.; Chambless, L.; Hu, Y.; Bang, H. Lipoprotein-associated phospholipase A2 and high-sensitivity Creactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study. Stroke, 2009, 40, 376-381.
63. Magyar, M.T.; Szikszai, Z.; Balla, J.; Valikovics, A.; Kappelmayer, J.; Imre, S.; Balla, G.; Jeney, V.; Csiba, L.; Bereczki, D. Earlyonset carotid atherosclerosis is associated with increased intimamedia thickness and elevated serum levels of inflammatory markers. Stroke, 2003, 34, 58-63.
64. Cao, J.J.; Thach, C.; Manolio, T.A.; Psaty, B.M.; Kuller, L.H. Creactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation, 2003, 108, 166-170.
65. Di Napoli, M.; Schwaninger, M.; Cappelli, R.; Ceccarelli, E.; Di Gianfilippo, G. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke, 2005, 36, 1316-29.
66. Lorenz, M.W.; Karbstein, P.; Markus, H.S.; Sitzer, M. Highsensitivity C-reactive protein is not associated with carotid intimamedia progression: the carotid atherosclerosis progression study. Stroke, 2007, 38, 1774-1779.
67. Dziedzic, T. Clinical significance of acute phase reaction in stroke patients. Front Biosci., 2008, 13, 2922-2927.
68. Kuo, H.K.; Yen, C.J.; Chang, C.H.; Kuo, C.K.; Chen, J.H.; Sorond, F. Relation of C-reactive protein to stroke, cognitive disorders and depression in the general population: systematic review and metaanalysis. Lancet Neurol., 2005, 4, 371-380.
69. Di Napoli, M.; Schwaninger, M.; Cappelli, R.; Ceccarelli, E.; Di Gianfilippo, G.; Donati, C.; Emsley, H.C.; Forconi, S.; Hopkins, S.J.; Masotti, L.; Muir, K.W.; Paciucci, A.; Papa, F.; Roncacci, S.; Sander, D.; Sander, K.; Smith, C.J.; Stefanini, A.; Weber, D. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke, 2005, 36, 1316-1329.
70. Shankar, A.; Li, J.; Nieto, F.J.; Klein, B.E.; Klein, R. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am. Heart J., 2007, 154, 495-501.
71. Schulze, H.C.; Ilg, R.; Sander, K.; Bickel, H.; Briesenick, C. Highsensitivity C-reactive protein at different stages of atherosclerosis: results of the INVADE study. J. Neurol., 2009, 256, 783-791.
72. Bo, M.; Corsinovi, L.; Brescianini, A.; Sona, A.; Astengo, M. High-sensitivity C-reactive protein is not independently associated with peripheral subclinical atherosclerosis. Angiology, 2009, 60, 12-20.
73. Abdellaoui, A.; Al-Khaffaf, H. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur. J. Vasc. Endovasc. Surg., 2007, 34, 18-22.
74. Kardys, I.; Knetsch, A.M.; Bleumink, G.S.; Deckers, J.W.; Hofman, A.; Stricker, B.H.; Witteman, J.C. C-reactive protein and risk of heart failure: The Rotterdam Study. Am. Heart J., 2006, 152, 514-520.
75. Ridker, P.M.; Rifai, N.; Lowenthal, S.P. Rapid reduction in Creactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation, 2001, 103, 1191-1193.
76. Albert, M.A.; Danielson, E.; Rifai, N.; Ridker, P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001, 286, 64-70.
77. Jialal, I.; Stein, D.; Balis, D.; Grundy, S.M.; Adams-Huet, B.; Devaraj, S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 2001, 103, 1933-1935.
78. Liberopoulos, E.N.; Daskalopoulou, S.S.; Mikhailidis, D.P.; Wierzbicki, A.S.; Elisaf, M.S. A review of the lipid-related effects of fluvastatin. Curr. Med. Res. Opin., 2005, 21, 231-244.
79. Okura, H.; Asawa, K.; Kubo, T.; Taguchi, H.; Toda, I.; Yoshiyama, M.; Yoshikawa, J.; Yoshida, K. Impact of statin therapy on systemic inflammation, left ventricular systolic and diastolic function and prognosis in low risk ischemic heart disease patients without history of congestive heart failure. Intern. Med., 2007, 46, 1337-1343.
80. Nissen, S.E.; Tuzcu, E.M.; Schoenhagen, P.; Crowe, T.; Sasiela, W.J.; Tsai, J.; Orazem, J.; Magorien, R.D.; O'Shaughnessy, C.; Ganz, P. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med., 2005, 352, 29-38.
81. Mora, S.; Ridker, P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol., 2006, 97, 33-41.
82. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M. Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359, 2195-2207.
83. Baigent, C.; Keech, A.; Kearney, P.M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, R. Cholesterol Treatment Trialists' (CTT) Collaborators.Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005, 366, 1267-1278.
84. Glynn, R.J.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M. Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Ridker, P.M. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med., 2009, 360, 1851-1861.
85. Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto A.M. Jr.; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; Macfadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J. JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009, 373, 1175-1182.
86. Spatz, E.S.; Canavan, M.E.; Desai, M.M. From Here to JUPITER Identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ. Cardiovasc. Qual. Outcome, 2009, 2, 41-48.
87. Michos, E.D.; Blumenthal, R.S. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J. Am. Coll. Cardiol., 2009, 53, 931-935.
88. Hlatky, M.A. Expanding the orbit of primary prevention-moving beyond JUPITER. N. Engl. J. Med., 2008, 359, 2280-2282.
89. Pearson, T.A.; Mensah, G.A.; Alexander, R.W.; Anderson, J.L.; Cannon, R.O. III.; Criqui, M.; Fadl, Y.Y.; Fortmann, S.P.; Hong, Y.; Myers, G.L.; Rifai, N.; Smith, S.C. Jr.; Taubert, K.; Tracy, R.P.; Vinicor, F. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 2003, 107, 499-511.
90. Ballantyne, C.M.; Hoogeveen, R.C.; Bang, H.; Coresh, J.; Folsom, A.R.; Chambless, L.E.; Myerson, M.; Wu, K.K.; Sharrett, A.R.; Boerwinkle, E. Lipoprotein-associated phospholipase A2, highsensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch. Intern. Med., 2005, 165, 2479-2484.
91. Melander, O.; Newton-Cheh, C.; Almgren, P.; Hedblad, B.; Berglund, G.; Engström, G.; Persson, M.; Smith, J.G.; Magnusson, M.; Christensson, A.; Struck, J.; Morgenthaler, N.G.; Bergmann, A.; Pencina, M.J.; Wang, T.J. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA, 2009, 302, 49-57.
92. Karabina, S.A.; Liapikos, T.A.; Grekas, G.; Goudevenos, J.; Tselepis, A.D. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim. Biophys. Acta, 1994, 1213, 34-8.
93. Mohler, E.R. III; Ballantyne, C.M.; Davidson, M.H.; Hanefeld, M.; Ruilope, L.M.; Johnson, J.L.; Zalewski, A.; Darapladib Investigators. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, doubleblind, placebo-controlled study. J. Am. Coll. Cardiol., 2008, 51, 1632-41.
94. Yasojima, K.; Schwab, C.; McGeer, E.G.; McGeer, P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol., 2001, 158, 1039-1051.
95. Torzewski, M.; Rist, C.; Mortensen, R.F.; Zwaka, T.P.; Bienek, M.; Waltenberger, J.; Koenig, W.; Schmitz, G.; Hombach, V.; Torzewski, J. C-reactive protein in the arterial intima: role of Creactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2094-2099.
96. Ouchi, N.; Kihara, S.; Funahashi, T.; Nakamura, T.; Nishida, M.; Kumada, M.; Okamoto, Y.; Ohashi, K.; Nagaretani, H.; Kishida, K.; Nishizawa, H.; Maeda, N.; Kobayashi, H.; Hiraoka, H.; Matsuzawa, Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation, 2003, 107, 671-674.
97. Ishikawa, T.; Hatakeyama, K.; Imanura, T.; Date, H.; Shibata, Y.; Hikichi, Y.; Asada, Y.; Eto, T. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am. J. Cardiol., 2003, 91, 287-292.
98. Ishikawa, T.; Imanura, T.; Hatakeyama, K.; Date, H.; Nagoshi, T.; Kawamoto, R.; Matsuyama, A.; Asada, Y.; Eto, T. Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation. Am. J. Cardiol., 2004, 93, 611-614.
99. Sabatine, M.S.; Morrow, D.A.; Jablonski, K.A.; Rice, M.M.; Warnica, J.W.; Domanski, M.J.; Hsia, J.; Gersh, B.J.; Rifai, N.; Ridker, P.M.; Pfeffer, M.A.; Braunwald, E. PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation, 2007, 115, 1528-1536.
100. Gaspardone, A.; Crea, F.; Versaci, F.; Tomai, F.; Pellegrino, A.; Chiariello, L.; Gioffrè, PA. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am. J. Cardiol., 1998, 82, 515-518.
101. Libby, P. Inflammation in atherosclerosis. Nature, 2002, 420, 868-874.
102. Hulthe, J.; Wikstrand, J.; Mattsson-Hulten, L.; Fagerberg, B. Circulating ICAM-1 (intercellular cell-adhesion molecule 1) is associated with early stages of atherosclerosis development and with inflammatory cytokines in healthy 58-year-old men: the Atherosclerosis and Insulin Resistance (air) Study. Clin. Sci. (Lond), 2002, 103, 123-129.
103. Devaraj, S.; Dasu, M.R.; Singh, U.; Rao, L.V.; Jialal, I. C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis, 2009, 203, 67-74.
104. Devaraj, S.; Xu, D.Y.; Jialal, I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003, 107, 397-403.
105. Chen, C.; Nan, B.; Lin, P.; Yao, Q. C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells. Thromb. Res., 2008, 122, 125-133.
106. Vaughan, D.E. PAI-1 and atherothrombosis. J. Thromb. Haemost., 2005, 3, 1879-1883.
107. Aso, Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci., 2007, 12, 2957-2966.
108. Blaschke, F.; Bruemmer, D.; Yin, F.; Takata, Y.; Wang, W.; Fishbein, M.C.; Okura, T.; Higaki, J.; Graf, K.; Fleck, E.; Hsueh, W.A.; Law, R.E. C-reactive protein induces apoptosis in human coronary vascular smooth cells. Circulation, 2004, 110, 579-587.
109. Nakajima, T.; Schuttle, S.; Warrington, K.J.; Kopecky, S.L.; Frye, R.L.; Goronzy, J.J.; Weyand, C.M. T-cell mediated lysis of endothelial cells in acute coronary syndromes. Circulation, 2002, 105, 570-575.